T.G. Cassegrain & Co.

Servier is a leading international pharmaceutical company governed by a non-profit foundation, headquartered in Suresnes, France. The company was established in its modern form in 1954 when Dr. Jacques Servier acquired the T.G. Cassegrain & Co. pharmaceutical laboratory in Orléans. Servier operates across five primary therapeutic areas: oncology, cardiovascular and metabolic diseases, neuroscience, and immuno-inflammation. In recent years, the company has significantly pivoted toward oncology, bolstered by the strategic acquisitions of Shire's oncology business and Agios Pharmaceuticals' oncology portfolio. As a foundation-led organization, Servier reinvests a substantial portion of its annual revenue into research and development, maintaining a robust pipeline of small molecules and biologics. The company maintains a global presence in over 150 countries and employs more than 21,000 people worldwide.